Company
Arcturus Therapeutics
Arcturus Therapeutics has 10 drugs tracked on RxWires: 1 in Phase 3, 1 in Phase 2/3, 4 in Phase 2, 3 in Phase 1/2, 1 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| ARCT-2303 | Phase 3 | COVID-19 |
| ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine | Phase 2/3 | COVID-19 Vaccines |
| ARCT-021 | Phase 2 | SARS-CoV-2 |
| ARCT-021 single dose priming | Phase 2 | Covid19 |
| ARCT-810 | Phase 2 | OTC Deficiency |
| ARCT-032 | Phase 2 | Cystic Fibrosis |
| ARCT-165 | Phase 1/2 | COVID-19 |
| ARCT-021 Dose 1 | Phase 1/2 | SARS-CoV-2 |
| ARCT-2304 | Phase 1/2 | Influenza, Human |
| ARCT-2138 | Phase 1 | Influenza, Human |
Latest
- arcturus therapeutics filed 8-K
- arcturus therapeutics filed 8-K
- arcturus therapeutics filed 8-K
- arcturus therapeutics filed 8-K
- arcturus therapeutics filed 8-K
Follow Arcturus Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.